# Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma.

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/activity-of-ofatumumab-ofa-a-fully-human-monoclonal-antibody-targeting-cd20/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Matthew J. Barth,Francisco J. Hernandez‐Ilizaliturri,Cory Mavis,Ping‐Chiao Tsai,John F. Gibbs,M. S. Czuczman |
| Citations | 6 |
| DOI | 10.1200/jco.2010.28.15_suppl.8095 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W11737159 |
| Type | conference-abstract |
| Year | 2010 |

## Paper authors

- [Ping‐Chiao Tsai](https://scholariq.org/researchers/ping-chiao-tsai/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)

## Paper topics

- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.